Fosun Health Capital

Fosun Health Capital's New Drug Innovation Fund, initiated by Fosun Pharma, is the first new drug innovation fund primarily focused on a holding incubation model. Established in August 2020, the fund’s first phase reached a scale of 1.5 billion RMB and finalized its closing in February 2021. The Fosun New Drug Innovation Fund mainly invests in early-stage and expansion-phase projects within the broader healthcare sector, prioritizing biopharmaceuticals with technological innovation and high growth potential. Leveraging six overseas VC partnerships under Fosun's existing network, the fund aims to introduce and localize world-class technologies and products from the global biotechnology field through collaboration models. The New Drug Innovation Fund will actively respond to the Chinese government's recent strong support for innovation in the biopharmaceutical industry, synergize with Fosun's R&D strengths and industrial layout, accelerate the development of invested projects within their respective technological domains, and promote overall innovation in China’s biopharmaceutical sector.